Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Espero Pharmaceuticals Selects DDB Health and Alamo Pharma Services as Partners for the Launch of GONITRO™ (Nitroglycerin) Sublingual Powder

Espero Pharmaceuticals,Inc.
Posted on: 31 Aug 16

Espero Pharmaceuticals, Inc., a privately held specialty pharmaceutical company, today announced that DDB Health, an Omnicom Health Group company, as its agency of record for GONITRO™. Omnicom is the largest healthcare marketing and communications group in the world.

Espero Pharmaceuticals has also partnered with Alamo Pharma Services, a leading pharmaceutical commercial solutions provider, to launch a stand-alone cardiovascular sales team dedicated to the promotion of GONITROTM. Alamo will assist with the recruiting, hiring and ongoing operational support for the Espero professional sales team.

“We are pleased to have DDB Health, the best creative team in cardiovascular marketing, to help us launch GONITROTM,” said Quang Pham, Chairman and CEO of Espero Pharmaceuticals. “With Alamo Pharma Services, we are able to recruit and attract outstanding sales candidates and have first-class operational support.”

“We are extremely excited at the opportunity to creatively and strategically partner with Espero Pharmaceuticals to introduce this innovative new option for patients who live with angina,” commented Patricia Malone, Senior Vice President and Creative Director, DDB Health.

“It is very exciting to have been chosen by Espero Pharmaceuticals,” added Peter Marchesini, Chief Operating Officer of Alamo Pharma Services. “This partnership will allow Alamo to provide our customized services, enabling Espero the opportunity to concentrate on revenue generating activities.”

GONITROTM is the first and only short-acting nitrate in a stabilized crystal granule form available in a single dose packet. Each individual packet of GONITROTM contains 400 mcg of nitroglycerin. The clinical data indicate that the sublingual absorption of nitroglycerin is higher following the administration of GONITROTM compared to Nitrolingual® Pumpspray (nitroglycerin lingual spray) which was launched in 1997 and is currently marketed by Espero in the United States. GONITROTM will be commercially available in September 2016.

Please see Full Prescribing information available at www.gonitrorx.com.

For more information regarding DDB Health, visit www.ddbhealth.com

For more information regarding Alamo Pharma Services, visit alamopharmaservices.com.

About Espero Pharmaceuticals

Espero Pharmaceuticals, Inc., www.esperopharma.com, headquartered in Jacksonville, Florida, is an emerging growth specialty pharmaceutical company engaged in maximizing the commercial value of proven treatments that improve the quality of life for patients.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160831005207/en/

Business Wire
www.businesswire.com

Last updated on: 31/08/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.